Investors reacted to Sybron Dental's (NYSE: SYD) fourth-quarter earnings announcement with about as much excitement as a Novocain-free root canal. Perhaps concerned with the pace of internal growth, fleeing shareholders sent shares down by more than 8% in midday trading on Tuesday.
Reported sales climbed 17%, while internal organic growth was pegged at about 12%. Sales were pretty well balanced, with the professional dental segment growing almost 13% on strong sales of cement and infection-prevention products and specialty-product sales climbing more than 10%, helped along by good sales in Damon self-ligating brackets.
Below the sales line, things get a bit foggier. Gross margin improved a bit, but the operating margin fell. Even if you exclude a $2 million asset impairment charge, the company still saw a decline in the operating margin from last year. An abnormally low tax rate helped compensate, though, and reported earnings per share rose 30% for the quarter.
On a brighter note, investors can take some solace in the cash flow picture. Free cash flow rose better than 27% for the entire fiscal year. Moreover, the company finished the year with a free cash flow yield of more than 12% -- a respectable mark by most normal standards. Last but not least, a low-to-mid-teens return on invested capital for the fiscal year is nothing to get depressed about.
There's a lot to like about Sybron. It has a nice consumables business and so doesn't seem quite as vulnerable to the vagaries of quarter-to-quarter spending decisions as does PattersonDental (Nasdaq: PDCO). What's more, there's the thought that dental care is relatively economically insensitive -- people get their teeth fixed in good times and bad.
I actually question that latter point, though. Dental care can be expensive, and many companies have curtailed or cut back dental coverage as part of cost-cutting measures. In addition, tough economic times can mean more people without work and no dental coverage at all. So while I respect the notion that health care in general can be a bulwark against bad times, I'm not sure that thesis is quite all that it's cracked up to be.
In all, Sybron is a well-run company and seems a bit more appealing than the likes of Patterson, Henry Schein (Nasdaq: HSIC), or Dentsply (Nasdaq: XRAY). And while I'm not terribly concerned about near-term growth prospects, I still don't see the stock as being within my preferred buy range just yet.
For more Foolish Takes:
Fools, now is the time to open your hearts and wallets to worthy causes! Please support our five Foolish charities at www.foolanthropy.com.
Fool contributor Stephen Simpson has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).
Terms & Conditions
RSS Headlines
Fool UK